Last reviewed · How we verify
NCT05906277: Melamoma4p
Biobanking and New Biomolecular Metrics
NA trial testing Biopsy in Melanoma (Skin) in 300 participants. Status unknown.
1 December 2022
Quick facts
| Lead sponsor | Regina Elena Cancer Institute |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 300 |
| Start date | 29 January 2019 |
| Primary completion | 1 December 2022 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Biopsy — full drug profile →
Conditions studied
- Melanoma (Skin) — all drugs for Melanoma (Skin) →
- Liquid Biopsy — all drugs for Liquid Biopsy →
Sponsor
Regina Elena Cancer Institute
Who can join
Eligibility, any sex, with Melanoma (Skin) or Liquid Biopsy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this Interventional study aims to apply, in our Institutes, a 4p oncological model i.e. predictive, personalized, of precision and participated (Regina Elena and San Gallicano).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Promising and Minimally Invasive Biomarkers: Targeting Melanoma.
Spiliopoulou P, Holanda Lopes CD, Spreafico A. · · 2023 · cited 6× · PMID 38201222 · DOI 10.3390/cells13010019
Verify or expand the search:
- PubMed search for NCT05906277
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Biopsy
Trials testing the same drug.
- NCT06675123 — Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lym · Phase 1 · recruiting
- NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn
- NCT07217990 — Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer · Phase 1, PHASE2 · not yet recruiting
- NCT06860815 — Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Br · Phase 2 · recruiting
- NCT05741164 — Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory · Phase 2 · not yet recruiting
Other recruiting trials for Melanoma (Skin)
Currently open trials in the same condition.
- NCT06643286 — Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma · NA · recruiting
- NCT06298734 — High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial · NA · recruiting
- NCT05704647 — Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases · Phase 2 · recruiting
- NCT05492682 — START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer · Phase 1 · active not recruiting
- NCT05649683 — Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors · NA · recruiting
Other Regina Elena Cancer Institute trials
Trials by the same sponsor.
- NCT07256769 — Vitamin k, D-chiro Inositol and α-lactalbumin in Bone Homeostasis · recruiting
- NCT07248878 — Pilot Study for the Generation of Cervical Cancer Organoids From Patients Undergoing Diagnostic Biopsy · recruiting
- NCT07258186 — Generation of Endometrial Carcinoma Organoids · recruiting
- NCT07018037 — Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma · recruiting
- NCT06894628 — Genomics and Efficacy of Post-prostatectomy Salvage Radiotherapy With 'Extreme' Hypofractionation · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05906277 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Regina Elena Cancer Institute
- Last refreshed: 15 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05906277.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing